Similar articles

• [Clinical experience with Danaparoid-sodium: measures to be taken in heparin-induced thrombocytopenia].

  [No authors listed] [No authors listed] Chirurg. 1998 Nov;69(11 Suppl Massnahme):1-4. Chirurg. 1998. PMID: 9853175 German. No abstract available.
• Treatment of heparin-induced thrombocytopenia.

  Peters FP. Peters FP. J Thorac Cardiovasc Surg. 1997 Sep;114(3):517-8. doi: 10.1016/S0022-5223(97)70219-8. J Thorac Cardiovasc Surg. 1997. PMID: 9305220 No abstract available.
• Cardiopulmonary bypass and heparin-induced thrombocytopenia: pitfalls of anticoagulation with danaparoid.

  Kanagasabay R, Unsworth-White MJ, Farnsworth G, Haxby EJ, Smith EE. Kanagasabay R, et al. J Thorac Cardiovasc Surg. 2000 Aug;120(2):428-9. doi: 10.1067/mtc.2000.108285. J Thorac Cardiovasc Surg. 2000. PMID: 10917979 No abstract available.
• New treatment options for heparin-induced thrombocytopenia.

  Ortel TL, Chong BH. Ortel TL, et al. Semin Hematol. 1998 Oct;35(4 Suppl 5):26-34; discussion 35-6. Semin Hematol. 1998. PMID: 9855181 Review.
• Management of patients with heparin-induced thrombocytopenia: focus on recombinant hirudin.

  Lubenow N, Greinacher A. Lubenow N, et al. J Thromb Thrombolysis. 2000 Nov;10 Suppl 1:47-57. doi: 10.1023/a:1027333320023. J Thromb Thrombolysis. 2000. PMID: 11155194 Review. No abstract available.